To view or add a comment, sign in Decoding VCT220 (CX11, gimaglipron): China's Oral GLP-1 Contender Alongside Orforglipron and HRS-7535 Following positive Phase 3 topline results in Chinese adults with obesity, VCT220 (Gimaglipron, CX11), discovered by Vincentage Pharma and now being developed globally by CORXEL Pharmaceuticals, has emerged as one of China's leading oral small-molecule GLP-1 receptor agonists, with NDA submission planned for obesity and potential expansion into type 2 diabetes
PMID 32611669
Therefore, monitoring creatinine levels during regular doctor visits is of great importance
Visible results can be seen as early as 1-2 weeks
Alternatively, allogenic mitochondria (from cell lines or unrelated donors) are being explored if they dont cause adverse immune reactions, they could be an off-the-shelf product for emergencies
ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror